All Q2 FY26 results →

BD

Becton, Dickinson and Company

Q2 FY26Health Care Equipment and Supplies

Becton, Dickinson and Company Q2 FY26 Results — Earnings Call Analysis

Q2 FY26 earnings call: what management said on revenue, margins and capex.

Price₹148

Market cap₹40.9K Cr

P/E25.8

Updated29 May 2026

Read4 min read

What the Q2 FY26 call signalled

1 of 3 strong

RevenueSlow growth

MarginMargins steady

CapexCapex planned

The short version

- Biologics now represent ~55% of Pharma Systems revenue, up from 50%, indicating strong growth in a high-growth category. - BD raised full-year adjusted EPS guidance to $12.52 - $12.72, reflecting confidence in growth amid dynamic environment.

From Becton, Dickinson and Company's Q2 FY26 earnings-call transcript · updated 29 May 2026.

Revenue & Sales Performance

Slow growth

Biologics now represent ~55% of Pharma Systems revenue, up from 50%, indicating strong growth in a high-growth category.
Multiple key growth platforms delivered double-digit growth in Q2, including biologic drug delivery, Advanced Patient Monitoring (APM), PureWick, and Advanced Tissue Regeneration.
Other areas like oncology, peripheral arterial disease, and Rowa pharmacy automation showed mid- to high single-digit growth.
BD expects revenue growth in the second half of the year to be roughly similar to the first half.
Headwinds from Alaris, vaccines, and China are expected to ease gradually: Alaris headwinds will peak in 2027 and then vanish by 2028.
Focus on innovation pipeline with higher margin, higher growth, and higher WAMGR markets.

2 more points from Becton, Dickinson and Company's call on revenue

Create a free account to keep reading this call

Profitability & Margins

BD raised full-year adjusted EPS guidance to $12.52 - $12.72, reflecting confidence in growth amid dynamic environment.
Alaris headwind of 200 basis points expected in FY '27, stabilizing in FY '28 with return to mid-single-digit growth in portfolio.
Innovation pipeline focused on high-growth, higher-margin markets supports margin expansion and revenue growth.
BD expects adjusted operating margins of ~25% inclusive of tariffs, with profitability ahead of expectations.
Continued productivity gains via BD Excellence, including 8% productivity achieved in Q2, expected to improve margins further in latter half of the year.
Revenue growth guidance of low single digits for FY '26 with strong contributions from biologic drug delivery and Advanced Patient Monitoring platforms.

2 more points from Becton, Dickinson and Company's call on margins

Create a free account to keep reading this call

See what Becton, Dickinson and Company said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned

BD is actively investing in focused growth platforms and innovation excellence to drive revenue growth.
The company is expanding its BD Excellence program, applying it beyond operations into commercial and R&D areas to improve efficiency and accelerate timelines.
Network architecture optimization continues, reducing sites to about 50, enabling investment in scaled facilities with informatics and AI capabilities.
Capex includes investments to support new product launches such as the Pyxis Pro (AI- and cloud-enabled) and innovations in pharmacy automation (Parata and Rowa).
BD maintains selective tuck-in M&A to supplement growth but prioritizes share repurchases given current stock valuation.

2 more points from Becton, Dickinson and Company's call on capex

Create a free account to keep reading this call

Fundraising & Capital Structure

The company emphasizes disciplined capital allocation with a focus on share repurchases over tuck-in M&A, given the current undervaluation of the stock.
They returned $2.3 billion to shareholders in the quarter, including $2 billion through share repurchases and $0.3 billion in dividends.
They retired $2.1 billion of debt in the quarter and maintain a net leverage target of 2.5x (currently at ~2.9x), highlighting balance sheet discipline.

2 more points from Becton, Dickinson and Company's call on fundraising

Create a free account to keep reading this call

See what Becton, Dickinson and Company said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The company highlights strong momentum and competitive traction, particularly with the Pyxis Pro launch, noting the largest competitive funnel in the history of the Alaris business.
Alaris has the largest competitive funnel ever, with about 150 basis points of share gains year-to-date.
Overall, the Alaris competitive funnel is at record levels, reflecting strong demand and execution.
Early customer response to Pyxis Pro, which includes AI-enabled features, has been positive, with 75% of wins being competitive conversions.
Sales teams report best service levels ever, supporting a strong commercial funnel.

2 more points from Becton, Dickinson and Company's call on order book

Create a free account to keep reading this call

Others in Health Care Equipment and Supplies this season

Insulet Corporation (Q2 FY26)
Insulet Corporation Q2 FY26 quarterly results analysis. Full year 2026 total company revenue growth guidance raised to 21%-23%; Omnipod revenue growth of 22%-24
Globus Medical, Inc. (Q2 FY26)
Globus Medical, Inc. Q2 FY26 quarterly results analysis. U.S. Market Cap $11,192, P/E 19.9. AI-powered earnings insights.
Align Technology, Inc. (Q2 FY26)
Align Technology, Inc. Q2 FY26 quarterly results analysis. Worldwide revenue growth for full-year 2026 is expected to be up 3% to 4% year-over-year. Market Cap
Solventum Corporation (Q2 FY26)
Solventum Corporation Q2 FY26 quarterly results analysis. Expectation of improved growth in 2026 compared to 2025, supporting trajectory toward LRP targets (Pag

Compare:vs Intuitive Surgical, Inc.vs Stryker Corporation vs Medtronic plc

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Becton, Dickinson and Company and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Becton, Dickinson and Company Q2 FY26 results?

- Biologics now represent ~55% of Pharma Systems revenue, up from 50%, indicating strong growth in a high-growth category. - BD raised full-year adjusted EPS guidance to $12.52 - $12.72, reflecting confidence in growth amid dynamic environment.

What is Becton, Dickinson and Company share price analysis?

Becton, Dickinson and Company currently shows a neutral. The stock trades at a P/E of 25.8 with a market cap of $40,893. Investors should review the full earnings analysis for detailed insights.

Is Becton, Dickinson and Company planning capital expenditure?

- BD is actively investing in focused growth platforms and innovation excellence to drive revenue growth.

Keep Becton, Dickinson and Company on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.